| 27 0 (0%) | 06-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.53  |
1-year : | 36.83 |
| Resists | First : | 27 |
Second : | 31.53 |
| Pivot price | 26.88 |
|||
| Supports | First : | 26.78 |
Second : | 26.65 |
| MAs | MA(5) : | 26.97 |
MA(20) : | 26.85 |
| MA(100) : | 20.06 |
MA(250) : | 16.16 |
|
| MACD | MACD : | 0.7  |
Signal : | 1 |
| %K %D | K(14,3) : | 99.4 |
D(3) : | 95.9 |
| RSI | RSI(14): 75.8 |
|||
| 52-week | High : | 27 | Low : | 9.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KALV ] has closed below upper band by 17.3%. Bollinger Bands are 90.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.02 - 27.15 | 27.15 - 27.27 |
| Low: | 26.64 - 26.79 | 26.79 - 26.94 |
| Close: | 26.76 - 26.99 | 26.99 - 27.21 |
KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.
Thu, 11 Jun 2026
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger - Stock Titan
Thu, 11 Jun 2026
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart - Stock Titan
Thu, 11 Jun 2026
KalVista (NASDAQ: KALV) CDO disposes equity in $27-per-share Chiesi deal - Stock Titan
Thu, 11 Jun 2026
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes - Stock Titan
Thu, 11 Jun 2026
KalVista Pharmaceuticals (NASDAQ: KALV) removes Common Stock from Nasdaq - Stock Titan
Thu, 11 Jun 2026
KalVista (KALV) acquisition closes; 43.15M shares tendered at $27.00 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 131.3 (%) |
| Shares Short | 12,050 (K) |
| Shares Short P.Month | 19,650 (K) |
| EPS | -3.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | -118.8 % |
| Operating Margin | -57.4 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.09 |
| Sales Per Share | 2.15 |
| EBITDA (p.s.) | -2.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -89 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.86 |
| PEG Ratio | 0 |
| Price to Book value | -540 |
| Price to Sales | 12.55 |
| Price to Cash Flow | -16.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|